<p>Therapy related myeloid malignancies are an increasingly recognized treatment complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents. topoisomerase II inhibitors and radiotherapy. but recently questions have been raised regarding the immunomodulatory agent lenalidomide. https://www.cridersvillehealthcare.com/product-category/jewellery/